Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.40 |
| ▸ | FEN1 | P39748 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177344 | 0.81 | FFAR1 (0.46) | ALOX5APFEN1MAPTGSK3AGSK3B | |
| SCHEMBL3169981 | 0.78 | PTPN1 (0.47) | PTPN1ALOX5APFEN1MAPTLMNA | |
| SCHEMBL3172789 | 0.75 | ALDH1A1 (0.40) | PTPN1ALOX5APFEN1MAPTALDH1A1 | |
| SCHEMBL3179028 | 0.73 | CCNB2 (0.38) | PTPN1ALOX5APFEN1MAPTLMNA | |
| SCHEMBL5659634 | 0.69 | CXCR1 (0.58) | ALDH1A1NPC1RAB9A | |
| SCHEMBL22656552 | 0.69 | POLB (0.50) | PTPN1MAPTLMNAPOLBCYP2C9 | |
| SCHEMBL28305621 | 0.69 | PTPN1 (0.63) | PTPN1MAPTLMNAPOLBCYP2C9 | |
| SCHEMBL2448079 | 0.68 | ALOX15 (0.57) | PTPN1MAPTLMNAPOLBCYP2C9 | |
| SCHEMBL18864110 | 0.68 | DDB1 (0.44) | PTPN1ALOX5APFEN1MAPTLMNA | |
| SCHEMBL27776102 | 0.68 | L3MBTL1 (0.52) | PTPN1MAPTLMNAPOLBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188291-B2 | Heteroaryl-substituted carboxamides and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20100016337-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2097382-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE | Sanofi-Aventis (FR) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008077507-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939181-A1 | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016337-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | TBXAS1, PTGIS, NOS2 | PTPN1 2335/4885ALOX5AP 378/4885FEN1 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.